Pharmaceutical

Drugmakers’ ‘doughnut hole’ deal to shave sales

October 1, 2010
Bloomberg News
Drugmakers including Pfizer Inc., AstraZeneca, Bristol-Myers Squibb Co. and Eli Lilly and Co. may provide more than $2 billion in drug discounts to senior citizens next year under a deal pharmaceutical companies made with the White House.
More

Lilly sues drug distributor over generic Zyprexa sales

September 29, 2010
Bloomberg News
Celesio's Lloyds Pharmacy and Aah Pharmaceuticals businesses sold about 800,000 tablets of generic Zyprexa before agreeing in 2008 to halt sales, Lilly said in a complaint filed in the High Court in London.
More

Lilly discovers social media

September 22, 2010
J.K. Wall
Eli Lilly and Co. launched its own blog this month, dubbed LillyPad, to try to start discussions about public policy and corporate social responsibility. The Indianapolis-based drugmaker also launched an accompanying Twitter feed.
More

Lilly wins reversal of class action in Zyprexa suit

September 10, 2010
Bloomberg News
A U.S. appeals court in New York threw out a September 2008 ruling that said plaintiffs could pursue as a group claims that Zyprexa marketing caused them to pay more for the drug than what it was worth. The plaintiffs were seeking $6.8 billion in damages.
More

Indiana to get share of Botox settlement

September 3, 2010
Associated Press
Botox maker Allergan Inc. said it would pay $600 million to settle a years-long federal investigation into its marketing of the drug. Indiana will get $636,000 of that money.
More

Appeals court ruling upholds Lilly's Evista patents

September 1, 2010
Bloomberg News
Eli Lilly and Co. won a court ruling Wednesday that blocks plans by Teva Pharmaceutical Industries Ltd. to sell a generic version of the Evista osteoporosis treatment before March 2014.
More

Lilly wins ban of generic Strattera pending appeal

August 31, 2010
Bloomberg News
The U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday granted Lilly's request to prevent sales until the court rules on a judge's decision invalidating a patent on the medicine.
More

Lilly wins further delay in sales of Strattera copies

August 26, 2010
Bloomberg News
Strattera generated U.S. sales of $445.6 million last year, and each day that Lilly can fend off generic competition would translate into an average $1.22 million in sales.
More

Diabetes research pioneer Kirtley dies at 96

August 25, 2010
Associated Press
Diabetics who control their disease with pills instead of frequent insulin injections can thank Dr. William R. Kirtley, a groundbreaking Eli Lilly researcher.
More

Pearl IRB first firm in state to pre-screen clinical drug trialsRestricted Content

August 21, 2010
Chris O'Malley
Two former Eli Lilly and Co. employees launched the firm that promises to attract more clinical trial business to the state.
More

Lilly gains panel's backing to expand Cymbalta use

August 19, 2010
Bloomberg News
Outside advisers to the Food and Drug Administration voted 8-6 Thursday in favor of a broader use of Cymbalta on the basis of studies in lower back pain and osteoarthritis of the knee.
More

Lilly wins temporary ban on sales of Strattera copies

August 19, 2010
Bloomberg News
The invalidation of Lilly's Strattera patent opened the door for as many as 10 companies to sell generic versions of the drug, which generated U.S. sales of $445.6 million last year as a treatment for attention deficit hyperactivity disorder.
More

Cancer drug developer Endocyte files for IPO

August 18, 2010
Scott Olson
The company, headquartered at Purdue Research Park, said the number of shares to be offered and their price range have yet to be determined.
More

Lilly Alzheimer's drug prospect only the latest to fail

August 18, 2010
Bloomberg News
A dozen potential products designed to slow or stop clumps of protein from forming in the brain, a condition linked to the disease since 1906, have failed in mid- to late-stage testing since 2003.
More

Lilly's Cymbalta helps chronic pain in U.S. review

August 17, 2010
Bloomberg News
Approval for the millions of Americans with chronic back or knee pain may add more than $500 million, or 16 percent, to Cymbalta's annual sales.
More

Lilly halts development of Alzheimer's drug

August 17, 2010
 IBJ Staff and Associated Press
Studies showed that the treatment did not slow the disease's progression. It's just the latest setback for the pharmaceutical giant, which lost a patent lawsuit over a major drug last week and faces an unprecedented number of patent expirations through 2014.
More

Lilly braces for plunge in profits

August 14, 2010
J.K. Wall
Indianapolis-based drugmaker Eli Lilly and Co. faces such an unprecedented string of patent expirations and an unheard-of loss of revenue that it's hard to picture what the company will look like in five years.
More

Eli Lilly loses patent lawsuit for Strattera

August 13, 2010
 IBJ Staff and Associated Press
Eli Lilly and Co. on Thursday lowered its revenue outlook for the year after it lost a patent lawsuit over its attention deficit hyperactivity drug Strattera. The patent had been set to expire in May 2017. Lilly plans to appeal.
More

Lilly among bidders for Denmark company, source says

July 30, 2010
Bloomberg News
Copenhagen-based health-care company Ascendis Pharma A/S received offers of about $400 million, an unidentified source said. Ascendis may choose a final bidder by early September.
More

Lilly loses appeal over patent for cancer drug Gemzar

July 28, 2010
 IBJ Staff and Bloomberg News
A U.S. appeals court Wednesday said a lower court was correct to invalidate a patent on the medicine that expires in 2013. Gemzar generated $1.36 billion in global sales in 2009.
More

New rules raise stakes for Lilly drug

July 21, 2010
J.K. Wall
Drugmakers testing experimental Alzheimer’s medicines—including Eli Lilly and Co.—got good news last week when the National Institute on Aging and the Alzheimer’s Association proposed new guidelines to make earlier diagnoses of the disease.
More

Lilly reveals plans to cut 340 IT jobs

July 15, 2010
J.K. Wall
The Indianapolis-based drugmaker eliminated 140 information technology jobs in June through retirements, resignations and some cuts. Another 115 cuts will be made this month, and the remainder by the end of the year.
More

Lilly's Alzheimer's gamble takes aim at $10 billion in patent losses

July 13, 2010
Bloomberg News
Both of Lilly's late-stage treatments are designed to reduce plaque in the brain called beta amyloid, thought by researchers to be a main contributor to Alzheimer's. A drug that stops or reduces memory loss caused by Alzheimer's may be worth more than $5 billion a year, an analyst says, helping Lilly overcome the coming patent losses on several important pharmaceuticals.
More

Lilly to cut 170 manufacturing jobs by year's end

July 12, 2010
J.K. Wall
Eli Lilly and Co. will cut 170 jobs—mostly in Indianapolis—from its manufacturing and quality division by the end of the year as it continues its efforts to slim down before losing revenue from patent expirations on its bestselling drugs.
More

Contract pharmaceutical research firm expands to New JerseyRestricted Content

July 10, 2010
J.K. Wall
Concentrics grows in spite of recession as drug companies look for help to handle patent expirations
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. why oh why does this state continue to elect these people....do you wonder how much was graft out of the 3.8 billion?

  2. i too think this is a great idea. I think the vision and need is there as well. But also agree with Wendy that there may be better location in our city to fulfill this vision and help grow the sports of hockey and figure skating in Indy. Also to help further develop other parts of the city that seem often forgotten. Any of the other 6 townships out side of the three northernmost could benefit greatly from a facility and a vision like this. For a vision that sounds philanthropic, the location is appears more about the money. Would really like to see it elsewhere, but still wish the development the best of luck, as we can always use more ice in the city. As for the Ice growth when they return, if schedules can be coordinated with the Fuel, what could be better than to have high level hockey available to go see every weekend of the season? Good luck with the development and the return of the Ice.

  3. How many parking spaces do they have at Ironworks? Will residents have reserved spaces or will they have to troll for a space among the people that are there at Ruth Chris & Sangiovese?

  4. You do not get speeding ticket first time you speed and this is not first time Mr.Page has speed. One act should not define a man and this one act won't. He got off with a slap on the wrist. I agree with judge no person was injured by his actions. The state was robbed of money by paying too much rent for a building and that money could have been used for social services. The Page family maybe "generous" with their money but for most part all of it is dirty money that he obtained for sources that are not on the upright. Page is the kind of lawyer that gives lawyers a bad name. He paid off this judge like he has many other tine and walked away. Does he still have his license. I believe so. Hire him to get you confiscated drug money back. He will. It will cost you.

  5. I remain amazed at the level of expertise of the average Internet Television Executive. Obviously they have all the answers and know the business inside and out.

ADVERTISEMENT